Funding
Series B · Biotech

Juvena Therapeutics raises $33.5m Series B for regenerative biologics

Bison Ventures, Eli Lilly, Jefferson Life Sciences and other investors participated in the financing.

Updated Oct 16, 2026By RoundOS Funding desk

Juvena Therapeutics raised $33.5 million in Series B financing on January 12. Participants included Bison Ventures, Eli Lilly and Company, Jefferson Life Sciences, Mubadala Capital and Manta Ray. The company develops regenerative biologics intended to restore tissue function.

Funding history

Series B · This round$33.5M

Sources

  1. Juvena Therapeuticsprojectstartups.com
  2. businesswire.com

Similar rounds

All Biotech rounds →
Guoke Brain-Computer

Beijing startup developing non-invasive wearable brain-computer interfaces that combine brain-signal detection, decoding and neural modulation.

UndisclosedSeed · Oct 23, 2026
Star Therapeutics

Biotechnology company discovering and developing antibody therapies for diseases with significant unmet need.

$200MPrivate financing · Oct 23, 2026
Pathos AI

Clinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.

$237MSeries E · Oct 23, 2026
Knowledge Work

Tokyo software company developing sales AI agents, an agent operating platform and consulting services for enterprise sales teams.

¥4.8BSeries C debt second close · Oct 23, 2026

Related